Mild shock therapy may ease anxiety and depression, but not chronic pain

Send a link to a friend  Share

[February 13, 2018] By Lisa Rapaport

(Reuters Health) - People with anxiety and depression might feel a little better after they get mild electric shock therapy, but it’s unclear how much it will help or whether this treatment might ease other conditions, researchers say.

The therapy, known as cranial electrical stimulation, delivers a current similar to that of a 9-volt battery through electrodes on skin to the brain. Researchers examined data from 26 clinical trials that randomly assigned some patients with a variety of chronic painful conditions to receive this therapy and others to get a placebo or dummy treatment or stick with usual care.

Most of these trials were too small or brief to offer conclusive evidence that cranial electrical stimulation works for headache, joint pain, musculoskeletal pain, headache, fibromyalgia, insomnia, or depression alone, the analysis found.

For people with both depression and anxiety, however, researchers found “low-strength” evidence of a modest benefit.

“If there is a benefit, it is probably not on average a large benefit, because when a treatment has an average benefit that is large this is usually pretty obvious even from a small number of studies or even studies of a small number of patients,” said lead study author Dr. Paul Shekelle, of the West Los Angeles Veterans Affairs Medical Center.

“But the benefit of cranial electrical stimulation does not have to be large for it to still be a useful additional option for treatment of these conditions, because for most of them we don’t have large benefit treatment options,” Shekelle said by email.

With depression and anxiety in particular, four of the five studies in the analysis were conducted more than 40 years ago using shock therapy devices that are no longer available, researchers note in the Annals of Internal Medicine.

In the largest and most current study, patients did report bigger reductions in depression and anxiety symptoms with shock therapy than with usual care that included antidepressants. But the study only enrolled 115 patients and lasted just five weeks.

If this study had found similar benefits after six months or a year, that might have offered “moderate” quality evidence of effectiveness, Shekelle said. And if a few additional studies of this size and duration got consistent results, then there might be “high quality” proof.

[to top of second column]

Cranial electrical stimulation appeared safe, or at least the review didn’t find evidence of serious side effects.

Amid a worsening opioid crisis, doctors and patients are increasingly considering this type of therapy as an alternative to prescription painkillers, many of which can be addictive. But based on the research to date, the evidence in support of cranial electrical stimulation is sparse, researchers concluded.

“This information is disappointing,” Dr. Wayne Jonas, executive director of Samueli Integrative Health Programs in Alexandria, Virginia, writes in an accompanying editorial.

Insufficient proof of effectiveness from this collection of mostly small, brief studies doesn’t necessarily mean cranial electrical therapy is ineffective, Jonas writes.

It might still not be the best use of money, though. At the military hospital where Jonas works, an electrical stimulation device costs the hospital $1,500. Active duty patients can get one for free, while others pay $300 out of pocket.

“It should be used only after physician evaluation and under proper supervision,” Jonas said by email.

“In our clinic we determine if a person may benefit and then try it under supervision in the clinic at least three times,” Jonas added. “If there is a benefit, we will provide a machine to take home after proper instruction and with ongoing follow-up and monitoring.”

SOURCE: http://bit.ly/2wYH0qu Annals of Internal Medicine, online February 12, 2018.

[© 2018 Thomson Reuters. All rights reserved.]

Copyright 2018 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.

 

Back to top